Didanosine: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>David E. Volk
m (Undo revision 100471722 by David E. Volk (Talk))
mNo edit summary
 
(One intermediate revision by one other user not shown)
Line 26: Line 26:


== External Links ==
== External Links ==
* {{DailyMed}}
{{CZMed}}[[Category:Suggestion Bot Tag]]
* {{MedMaster}}
* {{DrugBank}}

Latest revision as of 06:00, 7 August 2024

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.
Didanosine structure.jpg
didanosine
IUPAC name: see chemistry section
Synonyms: dideoxyinosine
Formula: C10H12N4O3

 Uses: HIV

 Properties: Reverse transcriptase inhibitor

 Hazards: see drug interactions

Mass (g/mol): CAS #:
236.2273 69655-05-6


Didanosine (DDI), or dideoxyinosine, is a potent HIV-1 reverse transcriptase inhibitor that also acts as a viral DNA chain terminator. Treatment with DDI after long-term AZT treatment has been beneficial. Didanosine is unusual among nucleoside analogs because it does not contain a regular base or regular sugar, but instead contains hypoxanthine attached to a dideoxy sugar. The absence of a 3'-hydroxy group on the sugar prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. DDI is metabolized to dideoxyadenosine triphosphate (ddATP), its putative active metabolite that competes with dATP. It is often taken with antacids because its stability is low under acidic conditions. It is sold under the brand names Videx® and Videx® EC. Possible toxic side effects including diarrhea, liver dysfunction, hyperuricemia, pancreatitis and peripheral neuropathy.

Chemistry

Its IUPAC chemical name is 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one and its chemical formula is C10H12N4O3 (MW 236.2273).


Drug Interactions

The effects and toxicity of didanosine is increased when taken with ganciclovir, tenofovir or valganciclovir. DDI levels may be reduced when taken with tipranavir. The risk of peripheral neuropathy toxicity is additive for the DDI/zalcitabine combination.

External Links

The most up-to-date information about Didanosine and other drugs can be found at the following sites.